TrialDrug design, development and therapy2021

No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.

Yu Kyong Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.